AGS-16C3F
Based on 1 Customer Validation
AGS-16C3F is an antibody-drug conjugate (ADC) targeting ENPP3. AGS-16C3F is composed of ENPP3-targeting Anti-ENPP3/CD203c Antibody (HY-P990315) linked to Monomethyl auristatin F (HY-15579) via a linker. AGS-16C3F has anti-tumor activity and can be used in the study of metastatic renal cell carcinoma (mRCC).
For research use only. We do not sell to patients.
- Purity: 99.81%
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
PDE3 |
AGS-16C3F (0.001-1350 nM, 96 h) has IC50 of 1.1 nM, 2.73 nM, 109.9 nM and 146.5 nM in ROSA KIT D816V, ROSA KIT D816V-Gluc, HMC-1.1 and HMC-1.2 cells, respectively, shows potent inhibitory activity against the proliferation of ROSA cells with high expression of CD203c[2].
AGS-16C3F (0.5-100 nM, 96-120 h) induces apoptosis and kills tumor cells with high expression of CD203c in ROSA KIT D816V, ROSA KIT D816V-Gluc, HMC-1.1 and HMC-1.2 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:ROSA KIT D816V, ROSA KIT D816V-Gluc, HMC-1.1 and HMC-1.2 cells
-
Concentration:0.5-100 nM
-
Incubation Time:96-120 h
-
Result:Significantly increased the proportion of apoptotic cells in ROSA cells (dose-dependent).
Had a low apoptosis rate in HMC-1 cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD-SCID γ mice injected with ROSA KIT D816V-Gluc (5 million cells)[2]
-
Dosage:1,4 mg/kg
-
Administration:i.v. once every 4 days, 4 times in total
-
Result:Significantly reduced the number of tumor cells in peripheral blood, bone marrow, and spleen, and decreased serum tryptase levels.
During treatment and after drug withdrawal, the luciferase activity (marker of tumor burden) of mice in the high-dose group continued to be lower than that in the control group, and disease recurrence was delayed.
Significantly prolonged the survival of mice.
Showed a significant increase in apoptotic cells in the mouse bone marrow, indicating that the anti-tumor effect was mainly achieved by inducing apoptosis.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[AGS-16C3F]
-
Synonyms
AGS-16M8F
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kollmannsberger C, et al. A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. Oncologist. 2021 Mar;26(3):182-e361. [Content Brief]
[2]. Zhang Y, et al. In vitro and in vivo efficacy of an anti-CD203c conjugated antibody (AGS-16C3F) in mouse models of advanced systemic mastocytosis. Blood Adv. 2019 Feb 26;3(4):633-643. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AGS-16C3F Related Classifications
HY-171544 Related Classifications
Powered by Bioz